Cyrus Therapeutics is a biopharmaceutical company based in Seoul, Korea. The company focuses on developing therapeutics, likely in the field of biotechnology or pharmaceuticals.

Cyrus Therapeutics

Cyrus Therapeutics is a leading biotechnology company that is discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. We are committed to making our mission—‘drugging the undruggable targets’—possible with small molecule drugs as well as new chemical modalities such as targeted protein degraders.

Paratus Investment

Timepolio Asset Management

Kolon Investment

Atinum Partners

Mirae Asset Capital

Mirae Asset Venture Investment

Green Cross Holding Corp

Cyrus Therapeutics, a specialized company in the development of anticancer drugs (represented by CEO Kim Byung-moon, hereinafter referred to as Cyrus), announced on the 8th (local time) that it presented three posters at the American Association for Cancer Research (AACR 2024).
In Cyrus' presentation at AACR for the third consecutive year, this time included additional preclinical results for 'GSPT1 (G1 to S phase transition 1) molecular glue degrader' and 'SOS1 (Son of sevenless homolog 1) inhibitor,' as well as new research results on 'CDK7 (Cyclin dependent kinase 7) inhibitor'.

https://lnkd.in/g7SfAcm5

We're excited to announce that Cyrus will be presenting three poster presentations at the AACR 2024 conference. We warmly invite you to come and see our posters on the afternoon of April 8th. Further details are provided below.

Yuhan Corporation Acquires Technology License for Anticancer Drug Candidate Targeting SOS1 Inhibition Mechanism

On March 7th, Yuhan Corporation announced that it has signed a technology license agreement with Cyrus Therapeutics and Kanaph Therapeutics for an anticancer drug candidate that utilizes the SOS1 inhibition mechanism. The total contract value is 20.8 billion won (excluding royalties based on net sales), and includes an upfront payment of 600 million won and milestone payments based on future development, approval, and sales.

https://lnkd.in/gfkZfYnR

사이러스 "SOS1 저해제·GSPT1 분해제, KDDF 과제 선정"

사이러스테라퓨틱스(이하 사이러스)는 항암제로 개발 중인 SOS1 저해제와 GSPT1 분해제가 국가신약개발사업단(단장 묵현상)이 주관하는 '2023년 제3차 국가신약개발사업 신약 R&D 생태계 구축 사업' 지원 과제로 선정됐다고 8일 밝혔다. 이번 지원 과제 선정으로 사이러스는 향후 2년간 국가신약개발사업단의 지원을 받아 2025년 하반기까지 2개 과제의 1상 임상시험계획(IND) 승인을 목표로 비임상 연구를 진행할 예정이다... 
출처 : 히트뉴스(http://www.hitnews.co.kr)

https://lnkd.in/g92nrhDz

유한양행-사이러스테라퓨틱스 "항암 표적치료제 공동연구"

https://lnkd.in/gieCq9VG

Metric
Company Name	Cyrus Therapeutics
Symbol
MSH ID	COM:CYRUSTX
Market	PRIVATE
Sector	Healthcare & Health Services
Industry	Biopharmaceuticals
Country	KR
Stage
Employee Count
Website	cyrustx.com
LinkedIn	cyrus-therapeutics
Founders

Metric
Market Cap
Enterprise Value
Monthly Web Traffic
Web Traffic Growth
Valuation
Raised Capital

Metric
Revenue
Revenue (LTM)
Revenue (NTM)
Gross Profit
EBITDA
Operating Income
Net Income
EPS
Diluted EPS
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin
Operating Profit Margin
EBITDA Margin
Net Profit Margin
Return on Equity
Return on Assets
Return on Capital Employed

CYRU

COM:CYRUSTX

Cyrus Therapeutics

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio
P/B Ratio
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio
EV Multiple

Metric
Days Sales Outstanding
Days Payables Outstanding
Days Inventory Outstanding
Operating Cycle
Cash Conversion Cycle
Asset Turnover

Metric
Operating Cash Flow
Free Cash Flow
Cash Flow to Debt
Operating Cash Flow/Sales
Free Cash Flow Yield

Metric
Cash & Equivalents
Accounts Receivable
Inventory
Goodwill
Debt to Capitalization
Debt to Assets
Current Ratio
Quick Ratio

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue
R&D to Revenue
SG&A to Revenue